Peter Langmuir, MD
Advertisement
Articles by Peter Langmuir, MD
eter Langmuir, MD, Executive Director, Medical Science AstraZeneca, discusses the vandetanib clinical trials.
Advertisement
Latest Updated Articles
Dr. Langmuir Discusses Vandetanib Clinical TrialsPublished: March 15th 2011 | Updated:
Dr. Langmuir Explains the Side Effects of VandetanibPublished: April 7th 2011 | Updated:
Vandetanib Advantages in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Dr. Langmuir on Vandetanib in Medullary Thyroid CancerPublished: March 15th 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
4
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
5